(Q33638831)

28 July 2017

1 reference

title

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion (English)

1 reference

28 July 2017

Horst WD

1

1 reference

28 July 2017

Preskorn SH

series ordinal

2

1 reference

28 July 2017

publication date

1 December 1998

1 reference

Journal of Affective Disorders

28 July 2017

published in

1 reference

28 July 2017

volume

51

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

237-254

1 reference

Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Placebo response in depression: a search for predictors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

(—)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Binding of antidepressants to human brain receptors: focus on newer generation compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Bupropion in depression. II. The role of metabolites in clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Bupropion in depression. I. Biochemical effects and clinical response.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Antidepressant profile of bupropion and three metabolites in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

GABA, depression and the mechanism of action of antidepressant drugs: a neuroendocrine approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

REM sleep enhancement by bupropion in depressed men.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Long-Term Antidepressant Treatment Decreases Spiroperidol-Labeled Serotonin Receptor Binding

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Bupropion Plasma Levels Intraindividual and Interindividual Variability

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Nefazodone and imipramine in major depression: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Nefazodone--a novel antidepressant--may increase REM sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

The pharmacokinetics of venlafaxine when given in a twice-daily regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Effects of bupropion on core body temperature of mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

Comparative efficacy and safety of bupropion and placebo in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900222-5

7 January 2021

10.1016/S0165-0327(98)00222-5

Identifiers

DOI

1 reference

28 July 2017

1 reference